» Articles » PMID: 20195565

[HIV-associated Neuropathies]

Overview
Journal Nervenarzt
Specialty Neurology
Date 2010 Mar 3
PMID 20195565
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Human immunodeficiency virus (HIV)-associated polyneuropathy has become the most common neurological complication of HIV infection and is one of the main risk factors for development of a neuropathy worldwide. Therefore HIV should always be considered as an underlying cause in patients with neuropathy. Many types of peripheral neuropathies are seen in HIV infection depending on the stage of infection. The inflammatory demyelinating neuropathies both acute (Guillain-Barré syndrome, GBS) and chronic (chronic inflammatory demyelinating neuropathy, CIDP) occur mainly at the time of seroconversion or early in the course of the disease while syndromes associated with opportunistic infections like CMV (i.e. polyradiculoneuropathy) occur in the late phase of HIV infection and are related to the loss of immune function. Distal symmetrical polyneuropathy (DSP) is the most common neuropathy in HIV-infected patients. We review the clinical manifestations, epidemiology, clinical diagnostics, pathophysiology and management strategies for HIV-associated polyneuropathies.

Citing Articles

A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients.

Moodley K, Bill P, Patel V Neurol Neuroimmunol Neuroinflamm. 2017; 4(2):e315.

PMID: 28054000 PMC: 5182055. DOI: 10.1212/NXI.0000000000000315.


The HIV-1 transgenic rat model of neuroHIV.

Vigorito M, Connaghan K, Chang S Brain Behav Immun. 2015; 48:336-49.

PMID: 25733103 PMC: 4753047. DOI: 10.1016/j.bbi.2015.02.020.


Acute hemiplegia as a rare presentation of infantile Guillain-Barre syndrome.

Al-Mendalawi M Saudi Med J. 2014; 35(11):1419.

PMID: 25399226 PMC: 4362134.


Influence of short-term glucocorticoid therapy on regulatory T cells in vivo.

Sbiera S, Dexneit T, Reichardt S, Michel K, van den Brandt J, Schmull S PLoS One. 2011; 6(9):e24345.

PMID: 21912688 PMC: 3166315. DOI: 10.1371/journal.pone.0024345.

References
1.
Hahn K, Triolo A, Hauer P, McArthur J, Polydefkis M . Impaired reinnervation in HIV infection following experimental denervation. Neurology. 2007; 68(16):1251-6. DOI: 10.1212/01.wnl.0000261245.36884.7c. View

2.
Apostolski S, McAlarney T, Hays A, Latov N . Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1. Immunol Invest. 1994; 23(1):47-52. DOI: 10.3109/08820139409063432. View

3.
Simpson D, Dorfman D, Olney R, McKinley G, Dobkin J, So Y . Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology. 1996; 47(5):1254-9. DOI: 10.1212/wnl.47.5.1254. View

4.
Pettersen J, Jones G, Worthington C, Krentz H, Keppler O, Hoke A . Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006; 59(5):816-24. DOI: 10.1002/ana.20816. View

5.
Martin C, Solders G, Sonnerborg A, Hansson P . Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology. 2000; 54(11):2120-7. DOI: 10.1212/wnl.54.11.2120. View